Multiple Sclerosis Drug Market Size & Share, by Drug (Immunomodulators, Immunosuppressants, Interferons); Medication Type (Oral, Injection); Type (Clinically Isolated Syndrome, Relapse-Remitting MS, Primary Progressive MS, Secondary Progressive MS); Treatment (Medications, Stem Cell Therapy, Physical Therapy, Plasma Exchange); End-user (Hospitals, Specialty, Clinics, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Request Free Sample Copy

Report ID: 1986
Published Date: Feb 14, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Multiple Sclerosis Drug Landscape

Biogen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Merck KGaA.
Janssen Pharmaceuticals Companies of Johnson & Johnson
Bristol-Myers Squibb Company
Cipla Inc.

Browse Key Market Insights with Data Illustration:

Multiple Sclerosis Drug Market Size & Share, Forecast Report 2033

In the News

Janssen Pharmaceutical Companies announced the approval of PONVORY by the U.S. Food and Drug Administration. Ponvory is an oral medication used for treating adults with relapsing multiple Sclerosis.
Biogen collaborated with Eisai Co., Ltd., for the co-promotion of multiple sclerosis treatments including Tecfidera, Tysabri, and Avonex in Japan.

Frequently Asked Questions (FAQ)

Factors such as, higher prevalence of multiple sclerosis, advancement in research and development, higher instances of women having multiple sclerosis and government efforts for the treatment is to drive the market growth.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023-2033.

High cost of treatment of multiple sclerosis, shortage of skilled professionals and challenges to develop the drugs for the treatment are few factors which are to hamper the market growth.

The major players in the market are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA., Janssen Pharmaceuticals Companies of Johnson & Johnson, Bristol-Myers Squibb Company, Cipla Inc., and so onâ€¦

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug, type, medication type, treatment, end user, and by region.

The oral segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Companies Dominating the Multiple Sclerosis Drug Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the multiple sclerosis drug market?

What would be the CAGR of multiple sclerosis drug market over the forecast period?

What are the challenges affecting the multiple sclerosis drug market growth?

Which region will provide more business opportunities for growth of multiple sclerosis drug market in future?

Who are the major players dominating the multiple sclerosis drug market?

How are the company profiles selected?

What are the segments in the multiple sclerosis drug market?

Which segment captures the largest market size in medication type in the multiple sclerosis drug market?